openPR Logo
Press release

Diabetes Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

10-09-2024 07:58 PM CET | Health & Medicine

Press release from: ABNewswire

Diabetes Pipeline Therapeutics, Assessment, Companies,

DelveInsight's, "Diabetes Pipeline Insight 2024" report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Diabetes Pipeline. Dive into DelveInsight's comprehensive report today! @ Diabetes Pipeline Outlook [https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key takeaways from the Diabetes Pipeline Report

* In October 2024:- Novo Nordisk A/S- This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.
* DelveInsight's Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment.
* The leading Diabetes Companies such as Daewoong Tradipitant, Janssen Biotech,Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
* Promising Diabetes Therapies such as Aspirin, DA-2811, Forxiga, TG103 , and others.

Stay ahead with the most recent pipeline outlook for Diabetes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Diabetes Treatment Drugs [https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diabetes Emerging Drugs Profile

* Enavogliflozin - Daewoong

Enavogliflozin (DWP 16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor. The molecule is in phase-3 clinical trials for type-2 diabetic treatment. Enavogliflozin demonstrates the lowering of blood sugar and safety in diabetic patients in phase 2 clinical trials.

* Golimumab - Janssen Biotech

Golimumab is a human IgG1 monoclonal antibody, derived from immunizing genetically engineered mice with human TNF. It inhibits soluble and transmembrane forms of TNF- by binding to their specific receptors and blocking in consequence their bioactivity. It is currently under Phase II development for the treatment of Type 1 diabetes mellitus.

Explore groundbreaking therapies and clinical trials in the Diabetes Pipeline. Access DelveInsight's detailed report now! @ New Diabetes Drugs [https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Parenteral
* intravitreal
* Subretinal
* Topical.
* Molecule Type

Diabetes Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type

Unveil the future of Diabetes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Diabetes Market Drivers and Barriers [https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Diabetes Pipeline Report

* Coverage- Global
* Diabetes Companies- Daewoong Tradipitant, Janssen Biotech,Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
* Diabetes Therapies- Aspirin, DA-2811, Forxiga, TG103, and others.
* Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Diabetes Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Diabetes Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Diabetes: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
* Pipeline Therapeutics
* Comparative Analysis
* Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
* Diabetes - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Diabetes companies' collaborations, Licensing, Acquisition -Deal Value Trends
* Diabetes Collaboration Deals
* Company-Company Collaborations (Licensing / Partnering) Analysis
* Company-University Collaborations (Licensing / Partnering) Analysis
* Late Stage Products (Phase III)
* Comparative Analysis
* Enavogliflozin: Daewoong
* Product Description
* Research and Development
* Product Development Activities
* Mid Stage Products (Phase II)
* Comparative Analysis
* Golimumab: Janssen Biotech
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Early Stage Products (Phase II/I)
* Comparative Analysis
* IMCY-0098: ImCyse
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Comparative Analysis
* ENT-001: Enthera
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Inactive Products
* Comparative Analysis
* Diabetes Key Companies
* Diabetes Key Products
* Diabetes- Unmet Needs
* Diabetes- Market Drivers and Barriers
* Diabetes- Future Perspectives and Conclusion
* Diabetes Analyst Views
* Diabetes Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diabetes-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Diabetes Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here

News-ID: 3685508 • Views:

More Releases from ABNewswire

Distill Laser Clinic Oakville Launches Fall
Distill Laser Clinic Oakville Launches Fall "Glow & Restore" Promotion Featuring …
Oakville, ON - Sep 12, 2025 - Distill Laser Clinic's Oakville location is excited to launch its exclusive "Glow & Restore" promotion this fall, combining the powerful skin-rejuvenating effects of Morpheus8 treatments with premium SkinCeuticals skincare products. Image: https://www.abnewswire.com/upload/2025/09/1a41c667b0e8dc421d3f300fd85ce8d1.jpg As the crisp autumn season approaches, many clients look to refresh and revitalize their skin following summer, and Distill's Oakville clinic [https://www.distilllaserclinic.com/distill-laser-clinic-oakville/] is answering that call with an innovative, dual-offer initiative. Morpheus8, a
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repair Services to Support St. Louis Park Homeowners
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold. Responding to a Growing Need for Water Damage Restoration Property owners across Minnesota are increasingly seeking
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Injury Attorneys Representation in Port Jefferson Station
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents. Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washing Prevents Long-Term Damage in Millsboro DE
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces. In

All 5 Releases


More Releases for Diabetes

Major Force in the Diabetes Pen Market 2025: Diabetes Fuels Surge In Demand For …
How Will the Diabetes Pen Market Grow, and What Is the Projected Market Size? The diabetes pen market is projected to grow from $29.24 billion in 2024 to $31.22 billion in 2025, at a CAGR of 6.8%. Growth is fueled by the rising need for managing diabetes, advancements in diabetes care, and an increasing focus on patient-friendly medication administration tools. The diabetes pen market is projected to grow strongly, reaching $40.17 billion
Diabetes Monitoring Devices Market: Regaining Its Glory| Ascensia Diabetes Care, …
The Latest Study Published by HTF MI Research on the "Diabetes Monitoring Devices Market'' evaluates market size, trend and forecast to 2029. The Diabetes Monitoring Devices market study includes significant research data and evidences to be a practical resource document for managers and analysts is, industry experts and other key people to have an easily accessible and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges
Prevalence of Diabetes Drives Opportunities for Type-2 Diabetes Market
The Type-2 Diabetes Market Analysis, 2023, by MarkNtel Advisors, presents a well-researched, detail-driven, and accurate study for the stakeholders. This analysis entails prominent aspects like trends, & recent developments, drivers, opportunities, challenges, & restraints, among other parameters, influencing the overall industry expansion across different locations. This report comprises data from historic years (2018-21) & the base year (2022) to put together an estimation of the forecast period (2023-28). According to Type-2 Diabetes Market
Reverse Diabetes with Dr. Merritt’s Diabetes Reversal Recipe
[November 26, 2020] – People suffering from diabetes always search for ways to lower blood sugar levels in their bodies. Diabetes treatment available costs you hundreds of dollars yearly and also restricts you to a diabetic diet. That hampers your mental health and well-being. Apart from this, eye problems, kidney failure, amputations are some of the physical problems diabetic patients face. Dr. Marlene Merritt (from the Merritt Wellness Center in
Emerging trends for Diabetes Care Devices Market 2020 astonishing growth by Worl …
The global diabetes care devices market is expected to reach US$ 39,382.3 Mn in 2027 from US$ 23,354.3 Mn in 2018. The market is estimated to grow with a CAGR of 6.1% from 2020-2027. Premium market insights recently published a report titled "Diabetes Care Devices Market Size and Forecast to 2026". The report includes an authentic and accurate research study into the global Diabetes Care Devices market based on a qualitative
Diabetes Treatment
Diabetes Treatment is a important way to help manage the healthy ,easy to use and improve the way of the treatment of blood glucose monitoring system. As living standards improve, an increasing obesity, the Diabetes Treatment has improved peoples living habits, disease control effect, is becoming more and more important. The global Diabetes Treatment market is valued at 43700 million US$ in 2018 and will reach 58000 million US$ by the end